Posted 20 February, 2024
Chromocell Therapeutics Corp IPO completed
IPO completed detected for ticker NYSE:CHRO in a 424B4 filed on 20 February, 2024.
This is the initial public offering by Chromocell Therapeutics Corporation ("Chromocell", the "Company", "we", "us" or "our").
Don't know how to trade IPO completion? Read Initial Public Offerings.
Overview of Chromocell Therapeutics Corp
Health Care/Life Sciences • Pharmaceuticals
Chromocell Therapeutics Corp. is a clinical-stage biotech company that engages in the development and commercialization of new therapeutics to alleviate pain. Its clinical focus is to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. The company was founded on March 19, 2021 and is headquartered in Freehold, NJ.Market Cap
$20.4M
View Company Details
$20.4M
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.